Study identifier:D3561C00002
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
An Efficacy and 2-Year Safety Study of Open-label Rosuvastatin in Children and Adolescents (aged from 6 to less than 18 years) with Familial Hypercholesterolaemia
Familial Hypercholesterolaemia
Phase 3
No
rosuvastatin calcium
All
315
Interventional
6 Years - 17 Years
Allocation: Non-randomized
Endpoint Classification: Safety/Efficacy
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Verified 01 Mar 2015 by AstraZeneca
AstraZeneca
-
No locations available
Arms | Assigned Interventions |
---|---|
Experimental: 1 | Drug: rosuvastatin calcium 5 mg, oral, once daily, 24 months Other Name: Crestor Drug: rosuvastatin calcium 10 mg, oral, once daily, 24 months Other Name: Crestor Drug: rosuvastatin calcium 20 mg, oral, once daily, 24 months Other Name: Crestor |